These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27343070)

  • 21. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
    Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
    Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
    Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
    Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
    Gelibter S; Orrico M; Moiola L; Dagna L; Filippi M; Yacoub MR
    J Neurol Sci; 2020 Nov; 418():117104. PubMed ID: 32871512
    [No Abstract]   [Full Text] [Related]  

  • 28. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
    Chu L; Balusha A; Casserly C; Berger W; Morrow SA
    Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Van Schependom J; Gielen J; Laton J; Nagels G
    Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
    Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
    Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: A case report.
    Workel HH; Wolfhagen MJHM; Bouwhuis JW; Kloosterziel ME
    Mult Scler Relat Disord; 2020 Jul; 42():102137. PubMed ID: 32408151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
    Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8
    Anagnostouli MC; Velonakis G; Dalakas MC
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34049996
    [No Abstract]   [Full Text] [Related]  

  • 38. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
    Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion.
    Garcia J; Hendel-Chavez H; De-Goer MG; L'Honneur AS; Dubessy AL; Taoufik Y; Stankoff B
    Mult Scler; 2021 Apr; 27(4):640-644. PubMed ID: 32686582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.